Recently, Hangzhou RoboCT Technology Development Co., Ltd., the world's leading exoskeleton technology company, announced its new investor, US-based Pappas Capital. The company also received financing support from its previous investor, Yuhang Financial Holdings Group. Taking this opportunity, RoboCT will further accelerate the deployment of its international business development, significantly increase the introduction and investment of talents in the fields of R&D and marketing around the globe， and further collaborate with leading research and clinical institutions to promote its RaaS-based rehab exoskeleton solutions. It is reported that RoboCT has already become the No.1 enterprise in the deployment and use of rehab exoskeletons globally.

Pappas Capital has a 29-year track record of investing in innovative life science and technology companies. The funds managed by Pappas Capital have successfully invested in over 100 early-stage startups, which have resulted in 25 products and technologies receiving approval from the US Food and Drug Administration (FDA). Having Pappas Capital as an investor creates new channels for diversified financing opportunities and partnerships to advance the commercialization of RoboCT’s products.

Art Pappas, the Managing Partner of Pappas Capital, recognized RoboCT’s technology, "We are pleased to support RoboCT in the development and commercialization of life-changing robotic products. The company’s rehab exoskeleton solutions have impressively demonstrated tremendous potential, significantly advancing medical outcomes and prioritizing patient care."

RoboCT has received continued support from existing investors who participated in the company’s Series A and A+ financing rounds, including leading domestic and international funds such as Fortune Capital, Bluerun Ventures, Essence Securities, and Poly Capital. With their support, RoboCT has built mass production lines, self-developed core components, abundant product matrices, and a successful business model. With the help of Naton Technology, RoboCT completed its strategic layout of early productization and clinical registration.

As a national high-tech enterprise, RoboCT is committed to the R&D and application of exoskeleton technology. To date, RoboCT has independently applied for more than 500 patents, among which more than 300 patents have been authorized. The UGO Series rehab exoskeleton also won the 2023 China Patent Silver Award. As an "Innovative Class II Medical Device", RoboCT's rehab exoskeleton product is the first to obtain the China NMPA registration certificate for neurorehabilitation, and the technology has been recognized as world-leading by top societies and associations.

RoboCT's innovative marketing strategy around “rehabilitation/robotics as a service" (RaaS), has been recognized by leaders in the exoskeleton industry. Digital therapy has become widely promoted among hospitals and rehabilitation institutions. RoboCT’s rehab exoskeleton has entered more than 560 rehabilitation institutions, disability federation institutions, and hospitals in the past two years, covering more than 92% of the provincial administrative regions in China, and has served more than 300,000 rehabilitation sessions. RoboCT’s KidGo children’s exoskeleton products have been newly approved for NMPA Class II medical device certificates, which will undoubtedly continue to help in market expansion.

WANG Tian, the founder and CEO of RoboCT, mentioned how the business started, "Exoskeleton is a product that can amplify and empower human body functions, satisfying the imagination of being stronger. The core of exoskeleton robotics is to solve the aging and elderly-care problem that everyone faces."

Undeniably, China's rapid development in robotics and manufacturing provides a good foundation for rehab exoskeleton development. With further marketization and popularization, it will continue to drive the innovation and development of rehabilitation around the globe. The competitiveness of RoboCT’s products will promote market competition and strengthen international interest.

Exoskeleton technology is an epoch-making technology that can provide humans with a fresh life experience. In terms of medicine, the exoskeleton can be applied to rehabilitation, helping the disabled regain their freedom of movement and improving their quality of life. In the consumer market, the exoskeleton may provide the elderly with a more comfortable living environment, allowing them to maintain social connections and self-care ability.

RoboCT is focused on continuous innovation of its products and improving the economics around exoskeletons to increase access to its transformational technology and ultimately benefit more patients. Hence, RoboCT looks forward to working with customers and partners around the world for a healthy future.